Literature DB >> 14610101

Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.

Markus P Schlaich1, Elisabeth Lambert, David M Kaye, Zygmunt Krozowski, Duncan J Campbell, Gavin Lambert, Jacqui Hastings, Anuradha Aggarwal, Murray D Esler.   

Abstract

There is growing evidence that essential hypertension is commonly neurogenic and is initiated and sustained by sympathetic nervous system overactivity. Potential mechanisms include increased central sympathetic outflow, altered norepinephrine (NE) neuronal reuptake, diminished arterial baroreflex dampening of sympathetic nerve traffic, and sympathetic neuromodulation by angiotensin II. To address this issue, we used microneurography and radiotracer dilution methodology to measure regional sympathetic activity in 22 hypertensive patients and 11 normotensive control subjects. The NE transport inhibitor desipramine was infused to directly assess the potential role of impaired neuronal NE reuptake. To evaluate possible angiotensin sympathetic neuromodulation, the relation of arterial and coronary sinus plasma concentrations of angiotensin II to sympathetic activity was investigated. Hypertensive patients displayed increased muscle sympathetic nerve activity and elevated total systemic, cardiac, and renal NE spillover. Cardiac neuronal NE reuptake was decreased in hypertensive subjects. In response to desipramine, both the reduction of fractional transcardiac 3[H]NE extraction and the increase in cardiac NE spillover were less pronounced in hypertensive patients. DNA sequencing analysis of the NE transporter gene revealed no mutations that could account for reduced transporter activity. Arterial baroreflex control of sympathetic nerve traffic was not diminished in hypertensive subjects. Angiotensin II plasma concentrations were similar in both groups and were not related to indexes of sympathetic activation. Increased rates of sympathetic nerve firing and reduced neuronal NE reuptake both contribute to sympathetic activation in hypertension, whereas a role for dampened arterial baroreflex restraint on sympathetic nerve traffic and a peripheral neuromodulating influence of angiotensin II appear to be excluded.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610101     DOI: 10.1161/01.HYP.0000103160.35395.9E

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  139 in total

1.  (In)activity-dependent alterations in resting and reflex control of splanchnic sympathetic nerve activity.

Authors:  Nicholas A Mischel; Patrick J Mueller
Journal:  J Appl Physiol (1985)       Date:  2011-10-06

Review 2.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 3.  Premise, promise, and potential limitations of invasive devices to treat hypertension.

Authors:  Elizabeth A Martin; Ronald G Victor
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

4.  NKCC1 upregulation disrupts chloride homeostasis in the hypothalamus and increases neuronal activity-sympathetic drive in hypertension.

Authors:  Zeng-You Ye; De-Pei Li; Hee Sun Byun; Li Li; Hui-Lin Pan
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

5.  Gut dysbiosis is linked to hypertension.

Authors:  Tao Yang; Monica M Santisteban; Vermali Rodriguez; Eric Li; Niousha Ahmari; Jessica Marulanda Carvajal; Mojgan Zadeh; Minghao Gong; Yanfei Qi; Jasenka Zubcevic; Bikash Sahay; Carl J Pepine; Mohan K Raizada; Mansour Mohamadzadeh
Journal:  Hypertension       Date:  2015-04-13       Impact factor: 10.190

6.  Exercise-induced inhibition of angiotensin II vasoconstriction in human thigh muscle.

Authors:  R Matthew Brothers; Mads L Haslund; D Walter Wray; Peter B Raven; Mikael Sander
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 7.  Pathogenesis of essential hypertension: historical paradigms and modern insights.

Authors:  Richard J Johnson; Dan I Feig; Takahiko Nakagawa; L Gabriela Sanchez-Lozada; Bernardo Rodriguez-Iturbe
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

Review 8.  How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Authors:  Kui Toh Gerard Leong; Henry Krum
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

9.  Autonomic function in hypertension; role of genetic variation at the catecholamine storage vesicle protein chromogranin B.

Authors:  Kuixing Zhang; Fangwen Rao; Brinda K Rana; Jiaur R Gayen; Federico Calegari; Angus King; Patrizia Rosa; Wieland B Huttner; Mats Stridsberg; Manjula Mahata; Sucheta Vaingankar; Vafa Mahboubi; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Douglas W Smith; Nicholas J Schork; Michael G Ziegler; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2009-02

10.  Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia.

Authors:  Cynthia Ashley; Danielle Burton; Yrsa B Sverrisdottir; Mikael Sander; David K McKenzie; Vaughan G Macefield
Journal:  J Physiol       Date:  2010-01-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.